Global EYLEA Drug Market is Segmented By Indication (Wet Age-Related Macular Degeneration (Wet AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV), and Others), By End User (Hospitals, Ophthalmic Clinics, and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Global EYLEA Drug Market Trends

  • Strategic collaborations and alliances: Increasing strategic collaboration among the industry players will aid in the market growth over the forecast period. For instance, in December 21, 2020, Bayer, a pharmaceutical company, announced its collaboration with social healthcare venture Arogya Finance, to introduce the Eylea Easy Pay Program in India to provide flexible and affordable payment solutions to help patients in India, accessing Eylea (aflibercept solution) treatment.

Global EYLEA Drug Market Regional Insights

  • North America is expected to be the largest market for EYLEA drug market during the forecast period, accounting for over 40.2% of the market share in 2023. The growth of the market in North America is due to increasing prevalence of eye diseases in North America.
  • The Europe market is expected to be the second-largest market for eylea drug market, accounting for over 25.4% of the market share in 2023. The growth of the market in Europe is due to rising geriatric population.
  • The Asia Pacific market is expected to be the fastest-growing market for eylea drug market, with a CAGR of over 21.3% during the forecast period. The growth of the market in Asia Pacific is due to rising diabetes population.

Figure 1. Global EYLEA Drug Market Share (%), By Region, 2023